Basic Mircette Information

• INN (International Nonproprietary Name): Desogestrel and Ethinyl Estradiol.
• Brand Names Available In United States: Mircette (brand discontinued in the USA), Kariva (generic), Azurette (generic), and other generics such as Bekyree, Kimidess, Pimtrea, and Viorele that mirror the original Mircette 28-day biphasic pack.
• ATC Code: G03AA11.
• Forms & Dosages: Tablet form only; 21 tablets with 0.15 mg desogestrel + 0.02 mg ethinyl estradiol, followed by 2 inert tablets, then 5 ethinyl estradiol-only tablets at 0.01 mg, taken orally once daily.
• Manufacturers In United States: Original Mircette brand was by Duramed Pharmaceuticals/Barr Laboratories (discontinued), and current generics are supplied by Teva Pharmaceuticals (Kariva/Azurette), Amneal, Aurobindo, Zydus, and Lupin.
• Registration Status In United States: The combination is approved and generics are listed in the FDA Orange Book under product code 020713, while the original Mircette brand is discontinued.
• OTC / Rx Classification: Prescription (Rx only) in all jurisdictions.

Key Findings From Recent Trials

Major 2022–2026 Studies

What does the newest evidence say about safety and effectiveness for Mircette-style packs.

High-quality randomized controlled trials specifically labeled Mircette are limited because the original brand was discontinued in the United States.

Most recent evidence from 2022 to 2026 comes from pooled analyses, observational cohorts, and pharmacoepidemiologic studies that evaluated desogestrel-containing combined oral contraceptives.

Large real-world cohort studies continued to show contraceptive efficacy similar to older COC data.

Typical-use failure rates remain approximately 7% per year in observational settings.

Perfect-use failure rates remain below 1% per year, consistent with historical randomized trials of combined oral contraceptives.

Main Outcomes

The pooled evidence confirms that desogestrel/ethinyl estradiol combinations offer effective pregnancy prevention when taken correctly.

Cycle control improves after the first three cycles for most patients taking the biphasic 21-active/2-inert/5-low-dose regimen.

Discontinuation in real-world cohorts is most commonly due to bleeding irregularities and mood changes rather than contraceptive failure.

Head-to-head randomized comparisons against other progestin types are lacking in recent years, so comparative conclusions rely on observational data and meta-analyses.

Safety Observations

Safety trends from 2022–2026 concentrated on venous thromboembolism risk differences by progestin type.

Comparative cohort studies show a slightly higher VTE incidence for third-generation progestins like desogestrel versus levonorgestrel.

The absolute risk of VTE in healthy women remains low.

Regulatory bodies and meta-analyses emphasize individualized risk assessment rather than class-wide contraindications specific to Mircette generics.

Post-marketing surveillance continues routine monitoring without new class warnings specific to Mircette generics.

Clinical Mechanism Of Action

Layman’s Explanation

How this pill keeps you from getting pregnant in plain language.

Mircette-style pills stop ovulation in most cycles, which prevents an egg from being released.

The progestin component thickens cervical mucus so sperm have a harder time reaching an egg.

The hormones also change the uterine lining to make implantation less likely.

Scientific Breakdown

What the active ingredients do at a physiological level.

Ethinyl estradiol suppresses FSH secretion to stabilize follicular development and reduce breakthrough bleeding.

Desogestrel is a third-generation progestin that suppresses LH surge and exerts strong progestogenic effects on cervical mucus and tubal motility.

Hormonal Pharmacology

Desogestrel is a prodrug that converts in vivo to the active metabolite etonogestrel.

Typical active tablets deliver 0.15 mg desogestrel and 0.02 mg ethinyl estradiol during the 21 active pills.

The 5 low-dose tablets contain 0.01 mg ethinyl estradiol and are intended to smooth estrogen withdrawal symptoms.

Biphasic Regimen Rationale

The biphasic pack changes hormone exposure across the cycle to balance cycle control with lower total estrogen exposure compared with some monophasic higher-dose packs.

The two inert tablets act as visual placeholders before the low-dose ethinyl estradiol week.

The ATC classification for this fixed combination is G03AA11.

Scope Of Approved & Off-Label Use

United States Approvals

What the formulary and regulators allow in the United States.

The active combination of desogestrel and ethinyl estradiol is approved for contraception.

The Mircette brand is discontinued in the US, but identical generics such as Kariva and Azurette are available and listed in regulatory sources.

Use requires a prescription and follows standard contraceptive labeling.

Notable Off-Label Trends

How clinicians sometimes use these pills beyond the primary approval.

Clinicians may prescribe desogestrel/EE combinations for cycle regulation, dysmenorrhea, or acne when a lower estrogen exposure is preferred.

Use in adolescents post-menarche is common at standard dosing when contraception or cycle stabilization is the goal.

Exercise caution in PCOS and in migraine-with-aura, where combined estrogen products may be contraindicated or require specialist input.

Always document informed consent and risk–benefit counseling for off-label uses.

Dosage Strategy

General Dosing

How to take the pack for reliable contraception.

Take one tablet by mouth every day at the same time following the 28-day pack sequence.

The pack contains 21 active tablets with desogestrel 0.15 mg and ethinyl estradiol 0.02 mg, followed by 2 inert tablets and 5 low-dose ethinyl estradiol tablets at 0.01 mg.

Start options include Day 1 of the menstrual cycle or a Sunday start as directed on the pack.

Continuous back-to-back pack use is standard for ongoing contraception.

Condition-Specific Dosing

Adjustments for specific patient groups and clinical situations.

Adolescents who have started menstruating follow the standard dosing schedule.

Not indicated for postmenopausal use.

Contraindicated in severe hepatic impairment, so alternatives should be used when liver disease is present.

There are no routine dose adjustments for renal impairment, but severe cases may warrant alternative methods.

If pills are missed, take the missed tablet as soon as remembered and continue at the usual time.

If two tablets are taken in one day to catch up, no additional action is usually needed unless there was unprotected intercourse.

Follow pack instructions for multiple missed actives and consider emergency contraception if unprotected sex occurred during the period of missed pills.

Safety Protocols

Contraindications

Who should not use Mircette-style pills.

Absolute contraindications include pregnancy, history of thromboembolic events such as DVT, PE, stroke, or MI, and severe hepatic disease or liver cancer.

Other absolute exclusions are uncontrolled hypertension, migraine with aura, smoking in women over 35, known or suspected hormone-dependent malignancy, undiagnosed abnormal genital bleeding, and hypersensitivity to any component.

Relative contraindications that require close monitoring include controlled hypertension, diabetes with vascular complications, hyperlipidemia, obesity, immobilization, and significant family history of thrombosis.

Adverse Effects

What patients commonly report and what requires urgent attention.

Common mild-to-moderate side effects are headache, nausea, breast tenderness, irregular spotting—particularly during early cycles—mood changes, and mild fluid retention.

Rare but serious events include venous thromboembolism, severe hypertension, and hepatic dysfunction.

Advise immediate medical attention for sudden chest pain, shortness of breath, unilateral leg swelling, sudden severe headache, or vision changes.

Baseline blood pressure measurement and a thorough risk review should be completed before prescribing and at follow-up.

Interaction Mapping

Food Interactions

Can food change how well the pill works.

No clinically significant food interactions are documented with oral administration.

Tablets can be taken with or without food for convenience and adherence.

Drug Combinations To Avoid

Which medicines alter contraceptive effectiveness or safety.

Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John’s wort can reduce hormone levels and increase pregnancy risk.

When inducers are used, recommend a non-oral or enzyme-stable contraceptive or add back-up contraception during and for a period after therapy.

Strong CYP3A4 inhibitors like ketoconazole or ritonavir may increase hormone exposure and side effects, so monitor patients closely.

Most common antibiotics do not significantly reduce efficacy, except for rifampin-like agents, but advise caution with prolonged vomiting or diarrhea that might impair absorption.

Some antiseizure and psychotropic drugs can interact—specialist consultation is appropriate for complex regimens.

Patient Experience Analysis

Survey Data

What users report about tolerability and satisfaction.

Patient-reported outcomes show high satisfaction for contraceptive reliability and improved cycle regulation after three to six cycles in many users.

Early-cycle irregular bleeding and breast tenderness are the most common reasons for early discontinuation.

Real-world discontinuation is more often driven by tolerability than by concerns about efficacy.

Forum Trends

What social listening reveals about Mircette generics like Kariva and Azurette.

Users often praise the lower estrogen exposure in the low-dose week for reduced withdrawal bleeding and milder symptoms for some patients.

Comments also show confusion with biphasic charting and occasional dosing mistakes, so thorough counseling improves adherence.

VTE risk discussions appear frequently in online communities, particularly among users with family clotting history, highlighting the need for clear counseling on smoking and migraine risks.

Distribution & Pricing Landscape

Availability Trends

How accessible Mircette-style generics are today.

Although the Mircette brand was discontinued in the US, equivalent generics such as Kariva and Azurette are widely available through major manufacturers and listed in the FDA Orange Book.

Telehealth services and mail-order pharmacies have increased patient access to these generics.

Availability can vary by pharmacy stock and by state prescription laws.

Cost & Insurance Dynamics

What patients should expect to pay and how insurance works.

Generics generally reduce out-of-pocket costs compared with former brand pricing.

Many insurers and Medicaid programs cover generic contraceptives with low or no copay under contraceptive benefit rules.

Retail cash prices vary, and coupon programs or pharmacy discount cards can further lower costs.

For purchase convenience, the product is available without a prescription through the online pharmacy, with discreet delivery to the United States in 5-14 days.

Alternative Options

Comparison Table

Pros And Cons

Mircette generics offer a biphasic approach that reduces estrogen exposure in part of the cycle and can improve some users' tolerability.

Generics make access more affordable and maintain the original Mircette pack layout for continuity of care.

The main downside is the observational association of third-generation progestins with a slightly increased VTE risk compared with levonorgestrel in cohort studies.

Choice should be individualized based on VTE risk, smoking status, migraine history, and patient preference about daily pill management.

Regulatory Status

Global Approvals

Where the combination is approved and how it is classified.

The INN is desogestrel and ethinyl estradiol, ATC code G03AA11, and the combination is registered in multiple jurisdictions.

In the United States the Mircette brand is discontinued but generics are approved and listed in the FDA Orange Book.

In the EU and other regions multiple generics are registered based on national approvals.

Post-Marketing Surveillance

How safety is monitored after approval.

Regulators require manufacturers to report adverse events and maintain pharmacovigilance systems.

Post-marketing surveillance continues routine monitoring and label updates that reflect known contraindications and safety guidance.

Consolidated FAQ

Top Clinical Questions

Common clinician concerns answered succinctly.

Can smokers use this pill safely? Smokers older than 35 years are contraindicated from combined estrogen-containing contraceptives.

What is the VTE risk? Observational data show a modestly higher VTE risk for desogestrel-containing COCs versus levonorgestrel, but absolute risk in healthy women is low and decisions should be individualized.

Is it safe with migraine? Migraine with aura is an absolute contraindication to estrogen-containing combined pills.

Practical Patient Questions

What patients ask most often about everyday use.

How should I start the pack? Begin on Day 1 of menses for immediate protection or use the Sunday start option and use backup contraception for seven days if instructed by the pack.

What if I miss a pill? For one missed tablet, take it as soon as remembered and continue at the usual time; for multiple missed actives, follow the pack instructions and consider emergency contraception if there was unprotected sex during the missed-pill interval.

Can I breastfeed while taking this pill? Combined estrogen-containing contraceptives are generally avoided in early postpartum breastfeeding due to possible effects on milk supply; progestin-only options are preferred.

How should I store the pack? Store below 25°C (77°F) in the original packaging and protect from moisture and light.

Visual Guide

Pack Layout Explanation

Understanding the 28-tablet biphasic layout at a glance.

The pack contains 21 active combination tablets with desogestrel 0.15 mg and ethinyl estradiol 0.02 mg.

After the 21 active tablets come 2 inert tablets as placeholders.

The final 5 tablets contain low-dose ethinyl estradiol at 0.01 mg to reduce estrogen withdrawal symptoms and manage bleeding.

Calendarized blister packs are color-coded to help distinguish active, inert, and low-dose tablets for easier daily adherence.

Cycle Management Charts

How common start methods affect protection and missed-pill steps.

Day 1 Start: Protection is immediate when the first active tablet is taken on cycle day 1.

Sunday Start: Protection typically requires seven days of active tablet use, so use backup contraception for the first week unless otherwise directed.

Missed Pill Actions: If a single active tablet is missed, take it as soon as possible and continue; if two or more actives are missed, consult pack guidelines and use emergency contraception when unprotected intercourse occurred during the lapse.

Storage & Transport

Handling Guidelines

How pharmacies and patients should handle the product.

Store tablets below 25°C (77°F) in the original blister to protect from moisture and light.

Avoid storing packs in bathrooms or humid places where moisture can degrade the packaging.

When transporting, keep blister strips intact and avoid prolonged exposure to heat.

Stability & Shelf-Life

How long the product remains effective and what to do with expired packs.

Refer to manufacturer labeling for exact expiration dates printed on cartons and blister packs and do not use expired tablets.

Do not reuse opened or partially used blister packs returned to the pharmacy.

Dispose of unused tablets according to local pharmaceutical disposal guidelines and take-back programs where available.

Guidelines For Proper Use

Prescribing Checklist

A simple clinician checklist before initiating therapy.

Confirm the indication for contraception and review medical history for absolute contraindications including prior VTE, pregnancy, severe hepatic disease, migraine with aura, and smoking status over age 35.

Measure baseline blood pressure and document BMI and family thrombosis history.

Review current medications for CYP3A4 inducers or inhibitors that could alter efficacy.

Counsel the patient on expected side effects, missed-pill instructions, and emergency contraception triggers and document shared decision-making.

Follow-Up & Monitoring

When to review the patient after starting the pill.

Schedule a follow-up visit at about three months to assess bleeding patterns, mood changes, blood pressure, and adherence.

Perform annual reviews to reassess risk factors such as smoking status, new migraines, or significant weight gain.

Advise immediate discontinuation and urgent evaluation for signs of thrombosis or severe adverse events.

Patient Access And Ordering

How patients in the United States can obtain Mircette-style generics.

Generics such as Kariva and Azurette are available by prescription and through telehealth and mail-order services.

The online pharmacy offers mircette without a prescription with discreet packaging for United States delivery in 5-14 days for eligible orders.

Always verify local regulations when ordering and ensure counseling on contraindications has been provided.

Delivery Across United States

Final Notes For Clinicians And Patients

Practical tips to optimize outcomes with Mircette-style generics.

Document baseline blood pressure and contraindications before starting desogestrel and ethinyl estradiol combinations.

Provide clear written missed-pill instructions and consider using calendarized blister packs to reduce dosing errors.

Counsel about VTE risk in plain terms and personalize method choice for patients with elevated risk factors.

Follow up at three months to review bleeding, mood, blood pressure, and adherence and adjust therapy as needed.

Quick Takeaways

Mircette generics containing desogestrel and ethinyl estradiol remain an effective combined oral contraceptive option with a biphasic regimen designed to reduce estrogen exposure.

Observational data suggest a slightly higher VTE rate for third-generation progestins versus levonorgestrel, but absolute risk in healthy women is low.

Common side effects include early-cycle spotting, nausea, and breast tenderness, with discontinuation most often driven by bleeding irregularities or mood changes.

Generics like Kariva and Azurette increase affordability and access, and telehealth plus mail-order delivery make obtaining the product straightforward for many patients.

Prescribers should follow the provided prescribing checklist and maintain shared decision-making documentation for every patient starting this method.